Update der antiretroviralen Therapie der HIV-Infektion

  • M. Flepp
Conference paper

Zusammenfassung

Die aktuelle Hoffnung, daß die progrediente Zerstörung des Immunsystems und der konsekutiv fatale Verlauf der HIV-Infektion durch eine antiretrovirale Therapie entscheidend beeinflußt, ja gar gestoppt werden könnte, beruht u. a. auf folgenden Voraussetzungen:

Neuen Erkenntnissen bezüglich der Pathogenese der HIV-Infektion, der Erkenntnis der Bedeutung der Viruskonzentration im Blut („viral load“) — zum einen als prognostischer Marker und zum andern als Marker zur Beurteilung der Wirksamkeit einer Behandlung -, der Verfügbarkeit von standardisierten Testmethoden wie PCR, bDNA oder NASBA zur Messung des „viral load“ auch außerhalb von Forschungslabors und schließlich der Verfügbarkeit von neuen, in Kombination verabreicht meist synergistisch wirkenden Medikamenten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123–126PubMedCrossRefGoogle Scholar
  2. 2.
    Wei X, Ghosh SK, Taylor ME et al (1995) Viral dynamics in Human immunodeficiency virus type-1 infection. Nature 373: 117–122PubMedCrossRefGoogle Scholar
  3. 3.
    Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-ldynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582–1586PubMedCrossRefGoogle Scholar
  4. 4.
    Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P (1995) Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 122: 573–597PubMedGoogle Scholar
  5. 5.
    Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167–1170PubMedCrossRefGoogle Scholar
  6. 6.
    O’Brien TR, Blattner WA, Waters D et al. (1996) Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 276: ???-???Google Scholar
  7. 7.
    Cocchi F, DeVico AL, Garzino-Demo A et al. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T-cells. Science 270: 1811–1815PubMedCrossRefGoogle Scholar
  8. 8.
    Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 270: 872CrossRefGoogle Scholar
  9. 9.
    Brien WA, Hartigan PM, Martin D et al. (1996) Changes in plasma HIV-1 RNA and CD4+ lymphozcyte counts and the risk oft progression to AIDS. N Engl J Med 334: 426–431CrossRefGoogle Scholar
  10. 10.
    Katzenstein DA, Hammer SM, Hughes MD et al. (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4+ cells per cubic millimeter. N Engl J M 335: 1091–1098CrossRefGoogle Scholar
  11. 11.
    Mayers, Douglas, Saravolatz Let al. (1996) Viral burdon measurements in CPCRA 007. X I ICAIDS, VancouverGoogle Scholar
  12. 12.
    Palumbo PE, Raskino C, Fiscus S et al. (1997) Correlation of HIV Plasma RNA Levels with Clinical Outcome in a Large Pediatric Trial (ACTG 152). 4th Conference on Retroviruses and Opportunistic Infections, January 22–26, Washington, DC, late breakerGoogle Scholar
  13. 13.
    Hammer SM (1996) Advances in antiretroviral therapy and viral load monitoring. AIDS 10 [Suppl 3]: S1–11PubMedGoogle Scholar
  14. 14.
    Murphy RL, Montaner J (1996) Nevirapine: a review of oits development, pharmaceutical profile and potential for clinical use. Exp Opin Invest Drugs 5: 1183–1199CrossRefGoogle Scholar
  15. 15.
    Deeks SG, Smith M, Holodniy M, Kahn JO (1997) HIV-1 protease inhibitors; a review for clinicians. JAMA 277: 145–153PubMedCrossRefGoogle Scholar
  16. 16.
    Delta Coordinationg Committee (1996) Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283–291CrossRefGoogle Scholar
  17. 17.
    Hammer SM, Katzenstein DA, Hughes MD et al. (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 335: 1081–1090PubMedCrossRefGoogle Scholar
  18. 18.
    Cooper D, Montaner J, Katlama C, Stoffels P, Scott J, McDade H et al. (1997) The CAESAR trial: final results. 4th Conference on Retroviruses and Opportunistic Infections. January 22–26, Washington/DC, Abstract 367Google Scholar
  19. 19.
    Perelson AS, Essunger P, Markowitz M, Ho DD (1996) How long should treatment be given if we had an anitretroviral regimen that completely blocke HIV replication? X I ICAIDS, VancouverGoogle Scholar
  20. 20.
    Subkommission Klinik (SKK) der Eidgenössischen Kommission für Aids-Fragen (EKAF) (1996) Richtlinien zu Behandlung der HIV-Infektion. Bull Bundesamt Gesundheitswesen 29: 5–7Google Scholar
  21. 21.
    Carpenter CCJ, Fischl MA, Hammer SM et al. for the International AIDS-Society USA (1996) Antiretroviral therapy for HIV infection 1996: recommendations of an international panel. JAMA 276: 146–154Google Scholar
  22. 22.
    Cameron DW et al. (1996) Prolongation of life and prevention of AIDS complication in advanced HIV immunodeficiency with ritonavir. XI International Conference on AIDS, July 7–12, VancouverGoogle Scholar
  23. 23.
    Henry K, Tierney C, Kahn J et al. for the ACTG 193A study team (1997) A randomized, double-blind, placebo-controlled study comparing combination nucleoside and triple therapy for the treatment of advanced HIV disease (CD4 50/mm3). 4th Conference on Retroviruses and Opportunistic Infections, January 22–26, Washington/DC, late breakerGoogle Scholar
  24. 24.
    Hirsch M for the protocol 039 study group (1997) Indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) in ZDV-experienced patients with CD4 cell counts 50 cells/mm3. 4th Conference on Retroviruses and Opportunistic Infections, January 22–26, Washington/DC, late breakerGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • M. Flepp

There are no affiliations available

Personalised recommendations